WALTHAM, Mass., October 1, 2015 /GLOBE NEWSWIRE/ – Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences.
Read Full Release
Millennia Portfolio Company, Histogenics, a regenerative medicine company, today announced the pricing of its underwritten initial public offering of 5,909,091 shares of its common stock at a price to the public of $11.00 per share.
Read Full Release
Histogenics Corp. announced the addition of Stephen Kennedy as Senior Vice President of Manufacturing, Operations, and Supply Chain, and Vladimir Scerbin as Vice President of Clinical Affairs.
Read Full Release
Histogenics Corp. has announced the appointment of Peter Greenleaf to Chief Executive Officer. Mr. Greenleaf brings over 20 years of experience in the biotechnology industry, most recently as President of MedImmune, the worldwide biologics arm of AstraZeneca.
Read Full Release
